Compare Ascendis Pharma A/S (ASND) vs Hut 8 Corp (HUT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Hut 8 Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Hut 8 Corp trades at $100.72 (market cap $11.50B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Hut 8 Corp nearer its low. Which is the better fit depends on your goals.
| ASND | HUT | |
|---|---|---|
Market Cap | $17.74B | $11.50B |
Sector | Health | Technology |
52-Week High | $277.18 | $133.02 |
52-Week Low | $163.32 | $19.45 |
Enterprise Value | $18.11B | $11.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
HUT trades at $102.22, down 3.77% over 24 hours, with a bearish technical signal and key support at $98. The company reported a net loss of $226.15 million in 2025 despite revenue growth, but recent earnings beats and a strategic pivot to AI infrastructure have driven positive analyst sentiment. Strong institutional backing is evident with $4.25 billion in project financing secured in June 2026.
Outlook remains speculative with high execution risk amid the business transition, though Wall Street consensus is bullish with a $135.63 price target. Key risks include sustained negative cash flow, competitive pressures in data centers, and reliance on successful AI project deployment to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
